EDGE vs. BRNS, CLRB, CLSD, VACC, ANIX, ELYM, IOBT, FGEN, ORMP, and GNLX
Should you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Barinthus Biotherapeutics (BRNS), Cellectar Biosciences (CLRB), Clearside Biomedical (CLSD), Vaccitech (VACC), Anixa Biosciences (ANIX), Eliem Therapeutics (ELYM), IO Biotech (IOBT), FibroGen (FGEN), Oramed Pharmaceuticals (ORMP), and Genelux (GNLX). These companies are all part of the "medical" sector.
Edge Therapeutics (NASDAQ:EDGE) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
Edge Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics.
Edge Therapeutics has a beta of 3.65, suggesting that its share price is 265% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500.
Edge Therapeutics received 172 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 66.79% of users gave Edge Therapeutics an outperform vote.
Barinthus Biotherapeutics has a consensus target price of $8.00, suggesting a potential upside of 229.37%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Edge Therapeutics.
In the previous week, Edge Therapeutics had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 6 mentions for Edge Therapeutics and 5 mentions for Barinthus Biotherapeutics. Edge Therapeutics' average media sentiment score of 0.00 beat Barinthus Biotherapeutics' score of -0.07 indicating that Edge Therapeutics is being referred to more favorably in the media.
28.0% of Edge Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 37.1% of Edge Therapeutics shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Barinthus Biotherapeutics' return on equity of -35.19% beat Edge Therapeutics' return on equity.
Summary
Edge Therapeutics beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks.
Get Edge Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edge Therapeutics Competitors List
Related Companies and Tools
